Evidence of SSX2 immunogenicity includes the detection of SSX2-specific antibodies in the serum of patients with melanoma, colon cancer and breast cancer [40] and the presence of CD8 T cells with specificity for SSX2 in tumor-infiltrated lymph nodes of patients with melanoma and hepatocarcinoma [41], [42]. The gene discussed is CD8A; the disease is melanoma.